IL2 and renal cell carcinoma: cG250 is currently marketed by WILEX AG under the trade name RENCAREX® and phase III trials have now been initiated using cG250 as an adjuvant therapy aimed at reducing recurrence in surgically-treated renal cell carcinoma (RCC) patients who have a high risk of relapse and in combination with interleukin 2 (IL-2) or IFN-α for metastatic RCC [4, 79, 92].